Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

What Was Tested

Researchers studied Insulin Glargine in this randomized controlled trial publication.

Who Took Part

The study group was 7637 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A total of 7637 patients in the DEVOTE trial, a treat-to-target, randomized, double-blind trial evaluating the CV safety of degludec vs glargine U100, were divided into three age groups (50-64 years, n = 3682; 65-74 years, n = 3136; ≥75 years, n = 819).

Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all-cause mortality, severe hypoglycaemia and serious adverse events (SAEs).

How the Study Was Run

The design is described as randomized and double-blind.

The patients were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Insulin Glargine.

What Was Measured

The subject headings attached to it are Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemia, Hypoglycemic Agents, Insulin Glargine and Insulin, Long-Acting.

Author keywords: basal insulin, hypoglycaemia and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized and double-blind study of Insulin Glargine in 7637 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Glargine compound page.